311 related articles for article (PubMed ID: 29093180)
1. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study.
Kiessling P; Lledo-Garcia R; Watanabe S; Langdon G; Tran D; Bari M; Christodoulou L; Jones E; Price G; Smith B; Brennan F; White I; Jolles S
Sci Transl Med; 2017 Nov; 9(414):. PubMed ID: 29093180
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic modelling of the anti-FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic.
Lledo-Garcia R; Dixon K; Shock A; Oliver R
CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):116-128. PubMed ID: 34735735
[TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.
Li T; Balthasar JP
J Pharm Sci; 2019 Jan; 108(1):714-724. PubMed ID: 30471293
[TBL] [Abstract][Full Text] [Related]
5. Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells
Qureshi OS; Sutton EJ; Bithell RF; West SM; Cutler RM; McCluskey G; Craggs G; Maroof A; Barnes NM; Humphreys DP; Rapecki S; Smith BJ; Shock A
MAbs; 2024; 16(1):2300155. PubMed ID: 38241085
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers.
Yap DYH; Hai J; Lee PCH; Zhou X; Lee M; Zhang Y; Wang M; Chen X
Clin Transl Sci; 2021 Sep; 14(5):1769-1779. PubMed ID: 33742786
[TBL] [Abstract][Full Text] [Related]
7. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Ulrichts P; Guglietta A; Dreier T; van Bragt T; Hanssens V; Hofman E; Vankerckhoven B; Verheesen P; Ongenae N; Lykhopiy V; Enriquez FJ; Cho J; Ober RJ; Ward ES; de Haard H; Leupin N
J Clin Invest; 2018 Oct; 128(10):4372-4386. PubMed ID: 30040076
[TBL] [Abstract][Full Text] [Related]
8. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses.
Blumberg LJ; Humphries JE; Jones SD; Pearce LB; Holgate R; Hearn A; Cheung J; Mahmood A; Del Tito B; Graydon JS; Stolz LE; Bitonti A; Purohit S; de Graaf D; Kacena K; Andersen JT; Christianson GJ; Roopenian DC; Hubbard JJ; Gandhi AK; Lasseter K; Pyzik M; Blumberg RS
Sci Adv; 2019 Dec; 5(12):eaax9586. PubMed ID: 31897428
[TBL] [Abstract][Full Text] [Related]
9. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.
Nnane IP; Han C; Jiao Q; Tam SH; Davis HM; Xu Z
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):13-21. PubMed ID: 28132416
[TBL] [Abstract][Full Text] [Related]
10. M281, an Anti-FcRn Antibody: Pharmacodynamics, Pharmacokinetics, and Safety Across the Full Range of IgG Reduction in a First-in-Human Study.
Ling LE; Hillson JL; Tiessen RG; Bosje T; van Iersel MP; Nix DJ; Markowitz L; Cilfone NA; Duffner J; Streisand JB; Manning AM; Arroyo S
Clin Pharmacol Ther; 2019 Apr; 105(4):1031-1039. PubMed ID: 30402880
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Robak T; Kaźmierczak M; Jarque I; Musteata V; Treliński J; Cooper N; Kiessling P; Massow U; Woltering F; Snipes R; Ke J; Langdon G; Bussel JB; Jolles S
Blood Adv; 2020 Sep; 4(17):4136-4146. PubMed ID: 32886753
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic effects of 4C9, an anti-FcRn antibody, in rats: implications for the use of FcRn inhibitors for the treatment of humoral autoimmune and alloimmune conditions.
Getman KE; Balthasar JP
J Pharm Sci; 2005 Apr; 94(4):718-29. PubMed ID: 15682382
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.
Bril V; Benatar M; Andersen H; Vissing J; Brock M; Greve B; Kiessling P; Woltering F; Griffin L; Van den Bergh P;
Neurology; 2021 Feb; 96(6):e853-e865. PubMed ID: 33219142
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
15. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
Dall'Acqua WF; Kiener PA; Wu H
J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
[TBL] [Abstract][Full Text] [Related]
16. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
Proetzel G; Roopenian DC
Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
[TBL] [Abstract][Full Text] [Related]
17. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
18. FcRn Inhibitor Therapies in Neurologic Diseases.
Alfaidi N; Karmastaji S; Matic A; Bril V
CNS Drugs; 2024 Jun; 38(6):425-441. PubMed ID: 38724842
[TBL] [Abstract][Full Text] [Related]
19. Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention.
Patel DD; Bussel JB
J Allergy Clin Immunol; 2020 Sep; 146(3):467-478. PubMed ID: 32896307
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
